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AdBDNF induced striatal neuronal recruitment in both R6/2 and WT mice. At 1 mo 
after AdBDNF injection (6 wk), R6/2 striata were double-stained for BrdU (green) and 
βIII-tubulin (red, A), NeuN (red, B), GAD67 (red, C), or DARPP-32 (red, D). Identi-
cally treated WT mice stained for the same markers are shown in E–H. Colabeling of 
BrdU with each neuronal marker was confirmed by confocal optical sectioning, with 
orthogonal views in the xz and yz planes (insets). Arrowheads denote double-labeled 
cells. Scale bars: 10 μm.
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induced neuronal addition and inte-
gration. (A) Density of BrdU+βIII-
tubulin+ cells in the striatum of 
R6/2 and WT mice injected once at 
4 wk of age with AdBDNF/AdNog-
gin (AdB/N), AdBDNF, AdNoggin, 
AdNull, or saline. (B–E) Newly gen-
erated neurons were recognized 
in both WT (B) and R6/2 (C–E) 
mice by confocal imaging of BrdU 
(green) colabeling with βIII-tubulin 
(red, B and C), DARPP-32 (red, 
D), or GAD67 (red, E). (F) Density 
of BrdU+ cells (green) coexpressing 
either DARPP-32, GAD67, enkeph-
alin (Enk), or SP in the striatum of 
AdBDNF/AdNoggin-, AdBDNF-, or 
AdNull-injected WT and R6/2 mice. 
(G and H) BrdU-tagged (green) 
enkephalinergic (red, G) and SP 
(red, H) neurons in R6/2 mice. (I and 
J) FG injection of the globus pallidus 
revealed BrdU-tagged striatal pro-
jection neurons in AdBDNF/AdNog-
gin-injected 11-wk-old WT (I) and 
R6/2 (J) mice. *P < 0.05, **P < 0.01, 
***P < 0.001, 1-way ANOVA fol-
lowed by post-hoc Bonferroni t tests. 
Arrows denote double-labeled cells. 
Scale bars: 10 μm.
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Newly generated striatal neurons as a function of disease and treatment
Treatment	 BrdU+	 BrdU+βIII-tubulin+	 BrdU+βIII-tubulin+	 	 	Post-hoc	comparison	(t	value)	
	 cells/mm3	 (%)	 cells/mm3	 Saline	 AdNull	 AdNoggin		 AdBDNF	 AdB/N
WT, saline 703 ± 174 0.5 ± 0.6 2.5 ± 3.0 0
WT, AdNull 938 ± 158 1.5 ± 0.5 21.3 ± 9.7 0.9 0
WT, AdNoggin 802 ± 92 2.7 ± 0.4 21.5 ± 7.2 0.82 0.01 0
WT, AdBDNF 1,278 ± 91 7.9 ± 1.8 116.9 ± 30.5 4.94A 5.03A 4.45A 0
WT, AdB/N 1,301 ± 91 16.7 ± 1.4 218.4 ± 19.4 9.32B 10.36B 9.16B 4.72A 0
R6/2, saline 425 ± 70 1.4 ± 1.7 6.4 ± 7.8 0
R6/2, AdNull 955 ± 139 1.8 ± 0.2 22.9 ± 6.5 0.52 0
R6/2, AdNoggin 874 ± 29 2.9 ± 0.4 24.7 ± 6.2 0.52 0.06 0
R6/2, AdBDNF 1,205 ± 118 11.4 ± 2.3 137.8 ± 34.1 3.66A 3.9B 3.4A 0
R6/2, AdB/N 1,583 ± 151 16.4 ± 2.3 268.0 ± 52.7 7.29B 8.32B 7.32B 3.92B 0
Total scored BrdU+ cells/mm3 and percent BrdU+βIII-tubulin+ cells as a function of treatment. These counts were used to predict the number of BrdU+βIII-
tubulin+ cells/mm3. Values are mean ± SEM. AdB/N, AdBDNF/AdNoggin. Statistical comparisons were made by 1-way ANOVA, followed by post-hoc Bon-
ferroni t test. AP < 0.01. BP < 0.001. n = 3 (saline); 7 (AdNull); 4 (AdNoggin, AdBDNF, and AdBDNF/AdNoggin).
Table 2
DARPP-32+ and GAD67+ medium spiny neuronal addition as a function of treatment
Treatment	 BrdU+	 DARPP-32+BrdU+	or	 DARPP-32+BrdU+	or	 	 Post-hoc	comparison	(t	value)	
	 cells/mm3	 GAD67+BrdU+	(%)	 GAD67+BrdU+	cells/mm3	 AdNull	 AdBDNF	 AdB/N
DARPP-32
WT, AdNull 679 ± 79 0.0 ± 0.0 0.0 ± 0.0 0
WT, AdBDNF 1,017 ± 195 5.9 ± 0.2 59.6 ± 10.0 2.84 0
WT, AdB/N 1,439 ± 95 4.7 ± 1.9 68.1 ± 28.0 3.24A 0.4 0
R6/2, AdNull 822 ± 132 0.0 ± 0.0 0.0 ± 0.0 0
R6/2, AdBDNF 1,350 ± 178 5.2 ± 0.3 69.8 ± 5.8 1.85 0
R6/2, AdB/N 1,651 ± 158 8.59 ± 4.6 125.6 ± 52.5 3.36A 1.51 0
GAD67
WT, AdNull 896 ± 215 0.4 ± 0.5 3.2 ± 3.7 0
WT, AdBDNF 1,166 ± 46 5.2 ± 0.1 60.1 ± 2.8 2.55 0
WT, AdB/N 1,297 ± 232 5.7 ± 2.3 80.3 ± 31.3 3.45A 0.9 0
R6/2, AdNull 938 ± 175 0.8 ± 0.6 9.7 ± 6.5 0
R6/2, AdBDNF 1,350 ± 161 4.6 ± 0.1 62.4 ± 8.1 2.03 0
R6/2, AdB/N 1677 ± 32 7.3 ± 2.0 124.4 ± 35.2 4.42B 2.39 0
Total scored BrdU+ cells/mm3 and percent DARPP-32+BrdU+ or GAD67+BrdU+ cells as a function of treatment. These data were used to predict the num-
ber of DARPP-32+BrdU+ or GAD67+BrdU+ cells/mm3. Values are mean ± SEM. AdB/N, AdBDNF/AdNoggin. Statistical comparisons were made by 1-way 
ANOVA followed by post-hoc Bonferroni t test. AP < 0.05. BP < 0.01. n = 4 per group.
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Newly generated enkephalin+ or SP+ MSNs as a function of treatment
	 BrdU+	 Enkephalin+BrdU+	or	 Enkephalin+BrdU+	or	 	 Post-hoc	comparison	(t	value)	
	 cells/mm3	 SP+BrdU+	(%)	 SP+BrdU+	cells/mm3	 AdNull	 AdBDNF	 AdB/N
Enkephalin
WT, AdNull 782 ± 33 0.0 ± 0.0 0.0 ± 0.0 0
WT, AdBDNF 1,017 ± 72 2.3 ± 0.5 23.1 ± 5.9 4.08A 0
WT, AdB/N 1,325 ± 186 3.6 ± 0.1 48.1 ± 7.3 7.8B 4.03A 0
R6/2, AdNull 873 ± 93 0.4 ± 0.5 4.2 ± 4.9 0
R6/2, AdBDNF 1,175 ± 85 3.0 ± 0.5 36.2 ± 7.7 1.96 0
R6/2, AdB/N 1,604 ± 171 4.8 ± 1.2 79.0 ± 21.5 4.53C 2.57 0
SP
WT, AdNull 756 ± 22 0.0 ± 0.0 0.0 ± 0.0 0
WT, AdBDNF 1,045 ± 17 2.5 ± 0.6 26.6 ± 5.6 4.78C 0
WT, AdB/N 1,287 ± 106 2.8 ± 0.7 35.3 ± 7.1 5.98B 1.56 0
R6/2, AdNull 803 ± 91 0.0 ± 0.0 0.0 ± 0.0 0
R6/2, AdBDNF 1,190 ± 195 2.6 ± 1.0 28.2 ± 12.3 1.99 0
R6/2, AdB/N 1,547 ± 198 4.3 ± 1.3 62.7 ± 15.9 4.41C 2.42 0
Total scored BrdU+ cells/mm3 and percent enkephalin+ or SP+BrdU+ cells as a function of treatment. These data were used to predict the number of 
enkephalin+BrdU+ or SP+BrdU+ cells/mm3. Values are mean ± SEM. AdB/N, AdBDNF/AdNoggin. Statistical comparisons were made by 2-way ANOVA fol-
lowed by post-hoc Bonferroni t test. AP < 0.05. BP < 0.001. CP < 0.01. n = 4 per group, with the exception of AdBDNF/AdNoggin-treated WT (n = 3).
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the  incidence  of BrdU+FG+ neurons  in  these 
striata. Nonetheless, 56.4 ± 19.9 neurons/mm3 
























New neurons were the product of antecedent neuronal mitogenesis. (A) Schematic of a 
mouse brain section through the striatum (STR) and lateral ventricle (LV) showing the 
locations of images in B–H (asterisks). CC, corpus callosum. (B) Striatal ventricular wall 
of an AdBDNF/AdNoggin-treated R6/2 mouse, given BrdU for 3 wk after viral injection at 
6 wk of age and sacrificed at 10 wk, immunostained for BrdU (green), βIII-tubulin (red), 
and Ki67 (blue), which is expressed by mitotically active cells. In the subventricular zone, 
actively dividing subependymal cells expressed Ki67, whereas BrdU+ daughter cells, the 
products of earlier divisions, did not. In the neostriatum within the same section, newly 
generated BrdU+ neurons identified by βIII-tubulin (C) or NeuN (D) did not express Ki67 
and thus showed no evidence of either persistent mitotic competence or aberrant cell 
cycle reentry. To the contrary, newly generated BrdU+βIII-tubulin+ (E) and BrdU+NeuN+ 
(F) neurons expressed the tumor suppressor p27kip1 (blue, E and F), a marker of mitotic 
quiescence. A cohort of BrdU+ cells in AdBDNF/AdNoggin-treated mice coexpressed the 
developmental migratory neuroblastic marker DCX (red, G and H); importantly, these 
BrdU+DCX+ cells were not found in AdNull-treated R6/2 striata at this age, indicating that 
the immigration of migrating neuroblasts into the R6/2 striatum was a function of AdBDNF/
AdNoggin treatment. Scale bars: 10 μm (B–F); 5 μm (G and H).
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Newly generated FG+ striatal cells as a function of treatment
Treatment	 BrdU+	cells/mm3	 BrdU+FG+	(%)	 BrdU+FG+	cells/mm3	 	 Post-hoc	comparison	(t	value)	
	 	 	 	 AdNull	 AdBDNF	 AdB/N
AdNull 989 ± 118 0.0 ± 0.0 0.0 ± 0.0 0
AdBDNF 1312 ± 183 2.1 ± 0.5 28.7 ± 9.4 1.9 0
AdB/N 1601 ± 89 3.5 ± 1.3 56.4 ± 19.9 3.8A 1.88 0
Total scored BrdU+ cells/mm3 and percent FG+BrdU+ striatal cells as a function of treatment. These data were used to predict the number of BrdU+FG+ 
cells/mm3. Values are mean ± SEM. AdB/N, AdBDNF/AdNoggin. Statistical comparisons were made by 1-way ANOVA followed by post-hoc Bonferroni t 
test. AP < 0.05. n = 3 per group.
Figure 4
Induced neurogenesis was associated with delayed disease progression and prolonged survival. (A and B) AdBDNF/AdNoggin-cotreated 
R6/2 mice exhibited slower deterioration of motor performance than did AdBDNF-treated or untreated control R6/2 mice. (A) Time of sustained 
rotarod performance as a function of time point and treatment, using a 300-s rotarod challenge. (B) Results of the same challenge as in A pre-
sented as the percent rotarod impairment (see Methods). (C) Open-field testing revealed that AdBDNF/AdNoggin-treated R6/2 mice sustained 
volitional explorative behavior, as manifested in spontaneous horizontal locomotion, longer than did mice treated with AdBDNF only or AdNull 
or left untreated. (D) Kaplan-Meier analysis revealed that survival was significantly extended in R6/2 mice injected with AdBDNF/AdNoggin 
compared with R6/2 mice injected with AdBDNF only or AdNull or left untreated. Pre, preoperative. *P < 0.05, **P < 0.01 versus AdNull and 
untreated; ‡P < 0.01 versus AdBDNF.
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Neuronal addition was associated with longer survival.  In  light of 
the motor performance increments noted in AdBDNF/AdNog-
gin-treated R6/2 mice, we asked whether treatment influenced 

















Post-hoc  analysis  confirmed  the  difference  in mean  survival 
between AdBDNF/AdNoggin-treated R6/2 mice  and AdNull-
Figure 5
Ara-C suppressed neuronal mitogenesis. (A) Number of newly generated striatal neurons in both R6/2 and WT mice after treatment with 
AdBDNF/AdNoggin or AdNull, both with and without infusion of the mitotic inhibitor Ara-C. Ara-C essentially abrogated AdBDNF/AdNoggin-
associated neuronal addition. (B–E) AdBDNF/AdNoggin-treated WT (B) and R6/2 (D) mice exhibited robust incorporation of BrdU (green) by 
subependymal progenitor cells. In contrast, Ara-C infusion potently suppressed mitotic activity within the subependyma, essentially abrogating 
neuronal addition to both WT (C) and R6/2 (E) neostriata. **P < 0.001. Scale bar: 100 μm.
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Striatal neuronal addition as a function of disease, treatment, and mitotic inhibition
Treatment	 BrdU+	 BrdU+βIII-tubulin+	 BrdU+βIII-tubulin+	 	 Post-hoc	comparison	(t	value)
	 cells/mm3	 (%)	 cells/mm3	 AdNull–Ara-C	 AdNull-saline	 AdB/N–Ara-C	 AdB/N-saline
WT, AdNull–Ara-C 145 ± 99.7 0 ± 0 0 ± 0 0
WT, AdNull-saline 985 ± 182 1.6 ± 0.03 14.5 ± 2.8 0.29 0
WT, AdB/N–Ara-C 128 ± 36.3 0.3 ± 0.3 1.2 ± 1.4 0.02 0.27 0
WT, AdB/N-saline 1584 ± 241 14.2 ± 2.5 248.4 ± 86.6 4.97A 4.67A 4.94A 0
R6/2, AdNull–Ara-C 197 ± 80.6 0 ± 0 0 ± 0 0
R6/2, AdNull-saline 938 ± 163 2.3 ± 0.6 19.4 ± 3.7 1.05 0
R6/2, AdB/N–Ara-C 233 ± 99.6 0 ± 0 0 ± 0 0 1.05 0
R6/2, AdB/N-saline 1809 ± 245 13.9 ± 1.6 292.6 ± 31.8 15.81A 14.77A 15.81A 0
Total scored BrdU+ cells/mm3 and percent BrdU+βIII-tubulin+ cells as a function of treatment. These counts were used to predict the number of BrdU+βIII-
tubulin+ cells/mm3. Values are mean ± SEM. AdB/N, AdBDNF/AdNoggin. Statistical comparisons were made by 1-way ANOVA followed by post-hoc Bon-
ferroni t test. AP < 0.01. n = 3 per group.
Figure 6
Ara-C inhibition of neurogenesis blocked the treatment-associated delay in disease progression. (A) Ara-C infusion blocked the relative pres-
ervation of R6/2 rotarod performance otherwise afforded by AdBDNF/AdNoggin treatment. (B) Rotarod impairment is shown as a function of 
time point and treatment. (C) Ara-C infusion similarly inhibited the relative maintenance of volitional explorative behavior exhibited by AdBDNF/
AdNoggin-treated R6/2 mice. (D) Kaplan-Meier analysis confirmed that survival was significantly extended in R6/2 mice injected with AdBDNF 
and AdNoggin, compared with AdNull-injected R6/2 mice, and revealed that the Ara-C–mediated inhibition of mitotic neurogenesis completely 
abrogated that survival benefit. *P < 0.05, **P < 0.01 versus Ara-C–infused AdBDNF/AdNoggin and saline-infused controls.
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neurogenesis  by  endogenous  progenitor  cells 
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